49 Clinical Trials for: “Glycogen Storage Disease Type II”, Page 1 of 3

Page 1 of 3 1 2 3 »

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Condition(s): Glycogen Storage Disease Type II; Pompe Disease; Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: July 6, 2009Completed

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Condition(s): Glycogen Storage Disease Type II; Pompe Disease; Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: March 14, 2011Completed

Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

Condition(s): Pompe Disease; Glycogen Storage Disease Type II; Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: August 4, 2009Completed

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Condition(s): Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: July 7, 2009Completed

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Condition(s): Pompe Disease (Late-onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: June 24, 2010Completed

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

Condition(s): Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: July 7, 2009Completed

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Patients With Infantile-Onset Pompe Disease Who Have Never Been Treated

Condition(s): Pompe Disease (Infantile-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenosis 2; Acid Maltase Deficiency Last Updated: May 2, 2013Recruiting

Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme^®

Condition(s): Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenesis 2 Acid Maltase Deficiency Last Updated: July 7, 2009Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Condition(s): Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenesis 2 Acid Maltase Deficiency Last Updated: April 4, 2013Recruiting

Extension Study of Long-Term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Condition(s): Pompe Disease Late-Onset; Glycogen Storage Disease Type II GSD II Last Updated: July 7, 2009Completed

Pompe Pregnancy Sub-Registry

Condition(s): Glycogen Storage Disease Type II (GSD-II); Pompe Disease (Late-onset); Glycogenesis 2 Acid Maltase Deficiency Last Updated: April 4, 2013Recruiting

Pompe Disease Registry

Condition(s): Glycogen Storage Disease Type II; Pompe Disease Last Updated: January 30, 2013Recruiting

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Condition(s): Glycogen Storage Disease Type II; Glycogenosis 2 Last Updated: April 12, 2012Approved for marketing

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Condition(s): Glycogen Storage Disease Type II; Glycogenosis 2 Last Updated: October 14, 2008Completed

Alglucosidase Alfa Temporary Access Program

Condition(s): Glycogen Storage Disease Type II (GSD-II); Pompe Disease (Late-onset); Acid Maltase Deficiency Disease; Glycogenosis 2 Last Updated: October 25, 2010Approved for marketing

Immune Tolerance Induction Study

Condition(s): Pompe Disease; Glycogen Storage Disease Type II (GSD-II); Glycogenesis 2 Acid Maltase Deficiency Last Updated: March 18, 2013Recruiting

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Condition(s): Pompe Disease; Glycogen Storage Disease Type II (GSD-II); Glycogenesis 2 Acid Maltase Deficiency Last Updated: March 23, 2011Completed

Growth and Development Study of Myozyme (Alglucosidase Alfa).

Condition(s): Pompe Disease; Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease Last Updated: March 14, 2013Recruiting

Extension Study of Long-Term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Condition(s): Pompe Disease Infantile-Onset; Glycogen Storage Disease Type II Last Updated: July 7, 2009Completed

Late-Onset Treatment Study Extension Protocol

Condition(s): Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD-II); Glycogenesis Type II; Acid Maltase Deficiency (AMD) Last Updated: January 10, 2012Completed

Page 1 of 3 1 2 3 »

ClinicalTrialsFeeds.org

NIH Clinical Trials Results via RSS

49 Clinical Trials for: “Glycogen Storage Disease Type II”, Page 1 of 3

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

A Study of rhGAA in Patients With Late-Onset Pompe Disease

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Patients With Infantile-Onset Pompe Disease Who Have Never Been Treated

Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme^®

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Extension Study of Long-Term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Pompe Pregnancy Sub-Registry

Pompe Disease Registry

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Alglucosidase Alfa Temporary Access Program

Immune Tolerance Induction Study

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Growth and Development Study of Myozyme (Alglucosidase Alfa).

Extension Study of Long-Term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Late-Onset Treatment Study Extension Protocol

Get These Results via Email or RSS

Subscribe via Web Newsreaders

Clinical Trials by Condition

Clinical Trials by Drug

Clinical Trials for Rare Diseases

Clinical Trials of Dietary Supplements

Clinical Trials by Sponsor

Clinical Trials by Location

About Clinical Trials Research

Site Details

49 Clinical Trials for: “Glycogen Storage Disease Type II”, Page 1 of 3

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

A Study of rhGAA in Patients With Late-Onset Pompe Disease

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Patients With Infantile-Onset Pompe Disease Who Have Never Been Treated

Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Extension Study of Long-Term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Pompe Pregnancy Sub-Registry

Pompe Disease Registry

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Alglucosidase Alfa Temporary Access Program

Immune Tolerance Induction Study

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Growth and Development Study of Myozyme (Alglucosidase Alfa).

Extension Study of Long-Term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Late-Onset Treatment Study Extension Protocol

Share Clinical Trials

Get These Results via Email or RSS

Subscribe via Web Newsreaders

Clinical Trials by Condition

Clinical Trials by Drug

Clinical Trials for Rare Diseases

Clinical Trials of Dietary Supplements

Clinical Trials by Sponsor

Clinical Trials by Location

About Clinical Trials Research

Site Details

Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme^®